The Top 5 Biosimilars Articles for the Week of March 4

March 8, 2019

The Center for Biosimilars® recaps the top news for the week of March 4, 2019.

Transcript:

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of March 4.

Number 5: The FDA has approved a subcutaneously administered version of the brand-name trastuzumab, Herceptin.

Number 4: Mylan revealed in its recent earnings call that it had an initial advisory meeting with the FDA regarding a proposed biosimilar referencing the brand-name Botox.

Number 3: During the European Crohn’s and Colitis Organisation’s14th Congress, held in Copenhagen, Denmark, researchers presented on real-world switches from reference infliximab to biosimilar CT-P13.

Number 2: Eli Lilly and Company is introducing a lower-priced authorized generic of its insulin lispro injection in the United States.

Number 1: FDA Commissioner Scott Gottlieb, MD, will be stepping down from his post in 1 month.

Finally, last week, our e-newsletter asked how important you think employers are to the US biosimilars market.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Content:

News | Business | Regulatory

x